



Express Mail No.: EV 335 857 375 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Hwu

Confirmation No.: 2126

Application No.: 10/001,281

Group Art Unit: 1614

Filed: November 30, 2001

Examiner: C. Ostrup

For: COMPOSITIONS AND
METHODS FOR THE
TREATMENT OF CANCER

Attorney Docket No.: 9516-026-999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 and 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to reference **BM**, which is listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant." A copy of reference **BM** is enclosed.

Identification of the listed reference is not to be construed as an admission that such reference is available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the reference identified on the attached Form PTO-1449, and that the reference be made of record in the file history of the above-identified application.

Pursuant to 37 C.F.R. §1.97(c), this Supplemental Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. §1.97(b) but before the mailing date of any of a final action under §1.113, a notice of allowance under §1.311, or an action that

otherwise closes prosecution in the application, and pursuant to 37 C.F.R. §1.97(c)(2) is accompanied by the fee set forth in §1.17(p) estimated to be \$180.00. Accordingly, please charge the required fee of \$180.00 to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this document is enclosed for accounting purposes.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

Date October 14, 2003

By: *Michael J. Bruner, Reg. No. 47,458* 35,203


Anthony M. Insogna (Reg. No.)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas

New York, New York 10036-2711

(212) 790-9090



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

9516-026-999

APPLICATION NO

10/001,281

APPLICANT

Wen-Jen Hwu

FILING DATE

November 30, 2001

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

BM	Hwu et al., "Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma", <i>J. of Clin. Oncol.</i> 21:3351-3356 (2003).

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.